Alogliptin

In the oxaliplatin-induced peripheral neuropathy model, oxaliplatin (4 mg/kg, Yakult Honsha Co., Ltd., Tokyo, Japan) or a vehicle (5% glucose solution) was injected intraperitoneally (i.p.) twice a week for four weeks (days 1, 2, 8, 9, 15, 16, 22, and 23). Paclitaxel (4 mg/kg, Sawai Pharmaceutical Co. Ltd., Osaka, Japan) or a vehicle (50% ethanol/50% Cremophor EL) was administered intraperitoneally (i.p.) twice a week for two weeks (days 1, 4, 8, and 11) for paclitaxel-induce neuropathy model. Bortezomib (0.2 mg/kg, i.p., Janssen Pharmaceutical K.K., Tokyo, Japan) or a vehicle (saline) was treated twice a week for two weeks (days 1, 4, 8, and 11) in Bortezomib model. Alogliptin (1 and 10 mg/kg, Sigma-Aldrich Co. LLC.) or a vehicle (distilled water) was administered orally (p.o.), five times a week for four weeks (days 1–5, 8–12, 15–19, and 22–26). Each drug was administered at a volume of 1 mL/kg. The doses of these drugs were determined based on previous reports^{30 (link),34 (link),36 (link)–38 (link)}.

Alogliptin (Sigma-Aldrich, MO) was given for 7 days at dose of 20 mg/kg/day p.o. ALO was suspended in 0.5% carboxymethyl cellulose (CMC) sodium to attain a last concentration of 2 mg/ml (Kabel 2018 (link)). Cyclophosphamide (CP) (Endoxan®, Baxter AG, Switzerland) was given as a sole-dose injection (200 mg/kg; i.p.) on day 2 to provoke acute lung toxicity. We dissolved CP in normal saline (0.9%) to a attain 2% concentration (20 mg/ml) (Caglayan et al. 2018 (link)). All other reagents and chemicals were commercially available.